A meta-analysis encompassing 16 clinical studies with T2DM patients having a baseline eGFR of 30–90 mL/min/1.73 m2 revealed that over 2 years, SGLT2i reduced UACR by 17%–33%, while GLP-1 RA achieved a 19%–22% reduction. The gene discussed is GCG; the disease is type 2 diabetes mellitus.